Skip to Main Content

Paper Details

First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC).
J Immunother Cancer
2
2023
Author NameAffiliation
Celestia S HiganoUniversity of Washington, Fred Hutchinson Cancer Research Center
  • 1 - 1

Datasets

Release 1.2